Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a…
8 of 9 participants (89%) treated in the 240mg and 360mg single dose cohorts achieved a complete response 8 of…
CINCINNATI, July 07, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ: QIPT; TSX: QIPT), a…
Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in…
SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or the “Company”, “we”, or…
Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medicationsTARRYTOWN, N.Y., June 24, 2025…
Emrosi™ (DFD-29; 40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) demonstrated efficacy independent…
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared…
Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal…
11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in…